.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,720,335

« Back to Dashboard

Details for Patent: 6,720,335

Title: Sulfonamide inhibitors of aspartyl protease
Abstract:The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
Inventor(s): Tung; Roger D. (Arlington, MA), Murcko; Mark A. (Holliston, MA), Bhisetti; Govinda Rao (Lexington, MA)
Assignee: Vertex Pharmaceuticals Incorporated (Cambridge, MA)
Filing Date:Mar 08, 2002
Application Number:10/094,763
Claims:1. A compound of formula I: ##STR654##

wherein: A is selected from the group consisting of Het; --R.sup.1 -Het; each R.sup.1 is independently selected from the group consisting of --C(O)--, --S(O).sub.2 --, --C(O)--C(O)--, --O--C(O)--, --O--S(O).sub.2, --NR.sup.2 --S(O).sub.2 --, --NR.sup.2 --C(O)-- and --NR.sup.2 --C(O)--C(O)--; each Het is independently selected from the group consisting 5-7 membered saturated or unsaturated heterocycle, containing one or more heteroatoms selected from N and N(R.sup.2), wherein said heterocycle may optionally be benzofused; and wherein said Het may be optionally substituted with one or more substituents selected from the group consisting of oxo, --OR.sup.2, --R.sup.2, --N(R.sup.2) (R.sup.2), --R.sup.2 --OH, --CN, --CO.sub.2 R.sup.2, --C(O)--N(R.sup.2) (R.sup.2), --S(O).sub.2 --N(R.sup.2) (R.sup.2), --N(R.sup.2)--C(O)--R.sup.2, --C(O)--R.sup.2, --S(O).sub.n --R.sup.2, --OCF.sub.3, --S(O).sub.n --Ar, methylenedioxy, --N(R.sup.2)--S(O).sub.2 (R.sup.2), halo, --CF.sub.3, --NO.sub.2, Ar and --O--Ar; each R.sup.2 is independently selected from the group consisting of H and C.sub.1 -C.sub.3 alkyl optionally substituted with Ar; with the proviso that when R.sup.2 is C.sub.1 -C.sub.3 alkyl substituted with Ar, said Ar may not be substituted with an Ar-containing moiety; B, when present, is --N(R.sup.2)--C(R.sup.3) (R.sup.3)--C(O)--; x is 0 or 1; each R.sup.3 is independently selected from the group consisting of H, Het, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.3 -C.sub.6 cycloalkyl and C.sub.5 -C.sub.6 cycloalkenyl, wherein any member of said R.sup.3, except H, may be optionally substituted with one or more substituents selected from the group consisting of --OR.sup.2, --C(O)--NH--R.sup.2, --S(O).sub.n --N(R.sup.2) (R.sup.2), Het, --CN, --SR.sup.2, --COR.sup.2, NR.sup.2 --C(O)--R.sup.2 ; each n is independently 1 or 2; D and D' are independently selected from the group consisting of Ar; C.sub.1 -C.sub.4 alkyl, which may be optionally substituted with one or more groups selected from C.sub.3 -C.sub.6 cycloalkyl, --OR.sup.2, --R.sup.3, --O--Ar and Ar; C.sub.2 -C.sub.4 alkenyl, which may be optionally substituted with one or more groups selected from the group consisting of C.sub.3 -C.sub.6 cycloalkyl, --OR.sup.2, --R.sup.3, --O--Ar and Ar; C.sub.3 -C.sub.6 cycloalkyl, which may be optionally substituted with or fused with Ar; and C.sub.5 -C.sub.6 cycloalkenyl, which may be optionally substituted with or fused with Ar; each Ar is independently selected from the group consisting of phenyl; 3-6 membered carbocyclic ring, wherein said carbocyclic ring may be saturated or unsaturated and optionally substituted with one or more groups selected from the group consisting of oxo, --OR.sup.2, --R.sup.2, --N(R.sup.2) (R.sup.2), --N(R.sup.2)--C(O)--R.sup.2, C.sub.1 -C.sub.3 alkyl substituted with --OH and optionally substituted with R.sup.7, --CN, --CO.sub.2 R.sup.2, --C(O)--N(R.sup.2) (R.sup.2), halo and --CF.sub.3 ; E is selected from the group consisting of Het.sub.E ; O-Het.sub.E ; Het.sub.E -Het.sub.E ; each Het.sub.E is independently selected from the group consisting 5-7 membered saturated or unsaturated heterocycle, containing one or more heteroatoms selected from N, N(R.sup.2) and O, wherein said heterocycle may optionally be benzofused; and wherein any member of said Het.sub.E may be optionally substituted with one or more substituents selected from the group consisting of oxo, --OR.sup.2, --R.sup.2, --N(R.sup.2) (R.sup.2), --R.sup.2 --OH, --CN, --CO.sub.2 R.sup.2, --C(O)--N(R.sup.2) (R.sup.2), --S(O).sub.2 --N(R.sup.2) (R.sup.2), --N(R.sup.2)--C(O)--R.sup.2, --C(O)--R.sup.2, --S(O).sub.n --R.sup.2, --OCF.sub.3, --S(O).sub.n --Ar, methylenedioxy, --N(R.sup.2)--S(O).sub.2 (R.sup.2), halo, --CF.sub.3, --NO.sub.2, Ar and --O--Ar; and each R.sup.4 is independently selected from the group consisting of --OR.sup.2, --C(O)--NHR.sup.2, --S(O).sub.2 --NHR.sup.2, halo, --NR.sup.2 --C(O)--R.sup.2 and --CN.

2. The compound according to claim 1, wherein said compound has the structure of formula XXII: ##STR655## wherein A, D' and E are defined as in claim 1.

3. The compound according to claim 1, wherein said compound has the structure of formula XXIII: ##STR656## wherein x=0 and Het, R.sup.3, D' and E are defined as in claim 1.

4. The compound according to claim 1, wherein said compound has the structure of formula XXXI: ##STR657## wherein A, R.sup.3, D' and E are defined as in claim 1.

5. A compound of formula I, wherein: A is --R.sup.1 -Het; each R.sup.1 is independently selected from the group consisting of --C(O)--, --S(O).sub.2 --, --C(O)--C(O)--, --O--CO--, --O--S(O).sub.2 -- and --NR.sup.2 --S(O).sub.2 --; each Het is independently selected from the group consisting of and 5-7 membered saturated or unsaturated heterocycle, containing one or more N, which may optionally be benzofused; wherein any member of said Het may be optionally substituted with one or more substituents selected from the group consisting of oxo, --OR.sup.2, --R.sup.2, --N(R.sup.2).sub.2, --R.sup.2 --OH, --CN, --CO.sub.2 R.sup.2, --C(O--N(R.sup.2).sub.2 and --S(O).sub.2 --N(R.sub.2).sub.2 ; each R.sup.2 is independently selected from the group consisting of H and C.sub.1 -C.sub.3 alkyl; B, when present, is --NH--CH(R.sup.3)--C(O)--; x is 0 or 1; R.sup.3 is selected from the group consisting of Het, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.3 -C.sub.6 cycloalkyl and C.sub.5 -C.sub.6 cycloalkenyl, wherein any member of said R.sup.3 may be optionally substituted with one or more substituents selected from the group consisting of --OR.sup.2, --C(O)--NH--R.sup.2, --S(O).sub.n --N(R.sup.2).sub.2, Het and --CN; n is 1 or 2; D and D' are independently selected from the group consisting of Ar; C.sub.1 -C.sub.4 alkyl, which may be optionally substituted with C.sub.3 -C.sub.6 cycloalkyl or Ar; C.sub.2 -C.sub.4 alkenyl, which may be optionally substituted with C.sub.3 -C.sub.6 cycloalkyl or Ar; C.sub.3 -C.sub.6 cycloalkyl, which may be optionally substituted or fused with Ar; and C.sub.5 -C.sub.6 cycloalkenyl, which may be optionally substituted or fused with Ar; Ar is selected from the group consisting of phenyl; 3-6 membered carbocyclic ring, wherein said carbocyclic ring may be saturated or unsaturated and optionally substituted with one or more groups selected from the group consisting of oxo, --OR.sup.2, --R.sup.2, --N(R.sup.2).sub.2, --N(R.sup.2)--C(O)R.sup.2, C.sub.1 -C.sub.3 alkyl substituted with --OH and optionally substituted with Ar, --CN, --CO.sub.2 R.sup.2, --C(O)--N(R.sup.2).sub.2, halo and --CF.sub.3 ; E is Het.sub.E ; each R.sup.4 is independently selected from the group consisting of --OR.sup.2, --C(O)--NHR.sup.2, --S(O).sub.2 --NHR.sup.2, halo and --CN; and each R.sup.5 is independently selected from the group consisting of H and R.sup.3.

6. The compound according to claim 2 or 3, wherein: A is R.sup.1 -Het; and D' is selected from the group consisting of C.sub.1 -C.sub.3 alkyl and C.sub.3 alkenyl, wherein said alkyl or alkenyl may optionally be substituted with one or more groups selected from the group consisting of C.sub.3 -C.sub.6 cycloalkyl, --OR.sup.2, --O--Ar and Ar.

7. The compound according to claim 3, wherein: R.sup.3 is selected from the group consisting of C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.5 -C.sub.6 cycloalkyl, C.sub.5 -C.sub.6 cycloalkenyl and a 5-6 membered saturated or unsaturated heterocycle, wherein any member of said R.sup.3 may optionally be substituted with one or more substituents selected from the group consisting of --OR.sup.2, --C(O)--NH--R.sup.2, --S(O).sub.n N(R.sup.2) (R.sup.2).sub.2, Het, --CN, --SR.sup.2, --C(O).sub.2 R.sup.2, NR.sup.2 --C(O)--R.sup.2 ; and D' is selected from the group consisting of C.sub.1 -C.sub.3 alkyl and C.sub.3 alkenyl, wherein said alkyl or alkenyl may optionally be substituted with one or more groups selected from the group consisting of C.sub.3 -C.sub.6 cycloalkyl, --OR.sup.2, --O--Ar and Ar.

8. The compound according to claim 4, wherein: A is R.sup.1 -Het; each R.sup.3 is independently C.sub.1 -C.sub.6 alkyl, which may be optionally substituted with a substituent selected from the group consisting of --OR.sup.2, --C(O)--NH--R.sup.2, --S(O).sub.n N(R.sup.2).sub.2, Het, --CN, --SR.sup.2, --CO.sub.2 R.sup.2, --NR.sup.2 --C(O)--R.sup.2 ; and D' is C.sub.1 -C.sub.4 alkyl, which may be optionally substituted with a group selected from the group consisting of C.sub.3 -C.sub.6 cycloalkyl, --OR.sup.2, --O--Ar and Ar; and E is selected from the group consisting of Het.sub.E, Het.sub.E -Het.sub.E.

9. The compound according to claim 1, wherein said compound has a molecular weight less than or equal to about 700 g/mol.

10. A compound according to claim 11, wherein said compound has a molecular weight less than or equal to about 600 g/mol.

11. A pharmaceutical composition effective against viral infection comprising a pharmaceutically effective amount of a compound according to any one of claims 1-4 and a pharmaceutically acceptable carrier, adjuvant or vehicle.

12. The pharmaceutical composition according to claim 11, further comprising an additional anti-viral agent.

13. A method for using of a compound according to any one of claims 1-4 as a therapeutic agent against viral infection, said virus requiring an aspartyl protease for an obligatory life cycle event.

14. The method according to claim 13, wherein said virus is HIV-1, HIV-2, or HTLV.

15. A method of inhibiting enzymatic activity in an aspartyl protease comprising the step of contacting the aspartyl protease with a compound according to any one of claims 1-4.

16. The method according to claim 15, wherein said aspartyl protease is HIV protease.

17. A method for preventing HIV infection in a mammal comprising the step of administering to said mammal a pharmaceutically effective amount of a pharmaceutical composition according to claim 11 or 12.

18. A method for treating HIV infection in a mammal comprising the step of administering to said mammal a pharmaceutically effective amount of a pharmaceutical composition according to claim 11 or 12.

19. The method according to claim 17 or 18, wherein said step of administering comprises oral administration or administration by injection.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc